Hasil Pencarian - Cathy D. Williams

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

    Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study oleh Anders Österborg, Roxanne C. Jewell, Swami Padmanabhan-Iyer, Thomas J. Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Marek Trnêný, Martin J.S. Dyer, Magdalena Piotrowska, Tomas Kozak, Ira V. Gupta, Jennifer L. Phillips, Nancy Goldstein, Herbert Struemper, Nedjad Losic, Steen Lisby, William G. Wierda

    Diterbitkan 2015-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

    Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim... oleh Graham H Jackson, Charlotte Pawlyn, David A Cairns, Ruth M de Tute, Anna Hockaday, Corinne Collett, John R Jones, Bhuvan Kishore, Mamta Garg, Cathy D Williams, Kamaraj Karunanithi, Jindriska Lindsay, Alberto Rocci, John A Snowden, Matthew W Jenner, Gordon Cook, Nigel H Russell, Mark T Drayson, Walter M Gregory, Martin F Kaiser, Roger G Owen, Faith E Davies, Gareth J Morgan, UK NCRI Haemato-oncology Clinical Studies Group

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

    Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial oleh Graham H. Jackson, Faith E. Davies, Charlotte Pawlyn, David A. Cairns, Alina Striha, Corinne Collett, Anna Waterhouse, John R. Jones, Bhuvan Kishore, Mamta Garg, Cathy D. Williams, Kamaraj Karunanithi, Jindriska Lindsay, David Allotey, Salim Shafeek, Matthew W. Jenner, Gordon Cook, Nigel H. Russell, Martin F. Kaiser, Mark T. Drayson, Roger G. Owen, Walter M. Gregory, Gareth J. Morgan, UK NCRI Haematological Oncology Clinical Studies Group

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: